Recent News From the Tseng Group:

UCLA Press Release of Our Circulating Tumor Cell Technology

UCLA did a press release of our Circulating Tumor Cell paper. The press release is starting to get picked up by several science news outlets, links below.

UCLA Press Release: UCLA researchers use ‘nano-Velcro’ technology to improve capture of circulating cancer cells
Physorg: Researchers use ‘nano-Velcro’ technology to improve capture of circulating cancer cells

If you see the story get picked up by any other outlets please leave a link in the comments. :)

Mitch (hand model, available for contract work)

Posted in Uncategorized | Leave a comment

Our Capture of Circulating Tumor Cells on Silicon Substrates Technology is in Angew

Finding a needle in a haystack: Our new technology is demonstrated to enrich circulating tumor cells (CTCs) with high efficiency by integrating an antibody-coated silicon nanopillar (SiNP, see picture; gray) substrate with an overlaid polydimethylsiloxane (PDMS) microfluidic chaotic mixer (turquoise). It shows significantly improved sensitivity in detecting rare CTCs from whole blood, thus providing an alternative for monitoring cancer progression.

This work got us the cover.

Link: Highly Efficient Capture of Circulating Tumor Cells by Using Nanostructured Silicon Substrates with Integrated Chaotic Micromixers


Posted in Uncategorized | 1 Comment

Angewandte VIP

We were recently selected to have our paper, “Delivery of Intact Transcription Factor Using Self-Assembled Supramolecular Nanoparticles”, as a VIP paper in Angewandte.

Link to announcement:

The paper will be available online within the next couple days.


Posted in Uncategorized | Leave a comment

Happy Chinese New Year from the Tseng Group

A picture from our recent Chinese new year lab dinner; a lot of good food and drink was had by all.


Posted in Uncategorized | Leave a comment

Beautiful Pic of Stained Cells

Hao took this amazing image of dapi stained cells today.

I think he is doing something wrong.


Posted in Uncategorized | 3 Comments

Our Latest Biomaterials Paper is Now Online

This is our grad student’s, Kuan-Ju Chen, first first-author paper. Woot!

Link to Paper: A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity

Nanoparticle Contrast Agent for MRI
Reprinted from Biomaterials Copyright (2010),
with permission from Elsevier

The work shows our nanoparticle system can be used as an in vivo MRI contrast agent.


Posted in Uncategorized | Leave a comment

We Got The Cover for ACS NANO!

Our latest paper was recognized with the cover of ACS Nano. It talks about our recent successes with delivering genes into cells. It also discusses our combinatorial approach which utilizes a microfluidic device.

It took Hao 9 months to write this paper so please have the pleasure of reading it.

Link to paper: A Rapid Pathway Toward a Superb Gene Delivery System: Programming Structural and Functional Diversity into a Supramolecular Nanoparticle Library


Posted in Uncategorized | Leave a comment

Author Profile in Angewandte

If you had your suspicions that our boss, Hsian-Rong Tseng, was a separating funnel in a previous life you were right! In the latest edition of Angewandte Chemie, the author profile is all about Tseng. You can read it here-> Author Profile: Hsian-Rong Tseng

DOI: 10.1002/anie.201005362


Posted in Uncategorized | 2 Comments

New Technician


We officially gained a new technician recently, Xiaowen Xu. She took this amazing photo of a cluster of cancer cells last week.

The image was stained with DAPI.

Posted in Uncategorized | 2 Comments

New diagnostic chip able to generate single-cell molecular ‘fingerprints’ for brain tumors

Read the full story at UCLA’s Newsroom:


New technologies for the diagnosis of cancer are rapidly changing the clinical practice of oncology. As scientists learn more about the molecular basis of cancer, the development of new tools capable of multiple, inexpensive biomarker measurements on small samples of clinical tissue will become essential to the success of genetically informed and personalized cancer therapies.

Researchers at UCLA have now developed a microfluidic image cytometry (MIC) platform that can measure cell-signaling pathways in brain tumor samples at the single-cell level. The new technology combines the advantages of microfluidics and microscopy-based cell imaging.

The ability to make these in vitro molecular measurements, or “fingerprints,” marks a new advance in molecular diagnostics that could ultimately help physicians predict patient prognosis and guide personalized treatment.

“The MIC is essentially a cancer diagnostic chip that can generate single-cell ‘molecular fingerprints’ for a small quantity of pathology samples, including brain tumor tissues,” said Dr. Hsian-Rong Tseng, a UCLA associate professor of molecular and medical pharmacology and one of the leaders of the research. “We are exploring the use of the MIC for generating informative molecular fingerprints from rare populations of oncology samples — for example, tumor stem cells.”

The research, which appears in the Aug. 1 issue of the journal Cancer Research, represents the teamwork of 35 co-authors from UCLA’s Jonsson Comprehensive Cancer Center with expertise in surgery, pathology, cancer biology, bioinformatics and diagnostic devices.

Led by Tseng and Thomas Graeber, an assistant professor of molecular and medical pharmacology, both of whom are researchers at the Crump Institute for Molecular Imaging at the David Geffen School of Medicine at UCLA and the California NanoSystems Institute (CNSI) at UCLA, the team analyzed a panel of 19 human brain tumor biopsies to show the clinical application of the MIC platform to solid tumors.

The researchers also developed new bioinformatics — computational and statistical techniques and algorithms — that allowed them to process and analyze the data gleaned from the MIC platform’s single-cell measurements.

“Because the measurements are at the single-cell level, computational algorithms are then used to organize and find patterns in the thousands of measurements,” Graeber said. “These patterns relate to the growth signaling pathways active in the tumor that should be targeted in genetically informed or personalized anticancer therapies.”

“The single-cell nature of the MIC brain tumor data presented an exciting and challenging opportunity,” said Dr. Nicholas Graham, a postdoctoral scholar at the CNSI who worked out the data analysis. “To make sense of the data, we had to develop some new bioinformatics approaches that would preserve the power of single-cell analysis but allow for comparison between patients.”

Molecular and medical pharmacology graduate researcher Michael Masterman-Smith approached the project as a translational cancer biologist.

“When we incorporated patient outcome data into our analyses and found that these ‘biosignatures’ clustered to reveal distinctive signaling phenomena that correlated with outcome, it got truly exciting,” he said.

Microscale technology platforms are finding wide application in biological assays in which careful manipulation and measurement of limited sample amounts are required, and the new MIC platform is capable of making molecular measurements on small tumor samples provided by tumor resection and biopsy using as few as 1,000 to 3,000 cells, according to the researchers.

“The promise and attractiveness of this approach is the small amount of tissue needed for analysis in the face of increasing numbers of prognostic and predictive markers, and the possibility of quantifying tumor genetic heterogeneity,” said Dr. William Yong, a Jonsson Cancer Center physician-scientist who led the pathology aspects of the research. “However, much work remains to validate this study with larger sample sizes and with more markers.”

“We are excited about the possibility of using this method to investigate responses of individual tumors to potential therapeutics, as well as to enhance our knowledge about how they become resistant to therapies,” said Dr. Harley Kornblum, a physician-scientist who studies brain tumor biology and is a member of both UCLA’s Intellectual and Developmental Disabilities Research Center and the Johnson Cancer Center cell biology program area.

“Scientific, medical and engineering disciplines each have their own approach to problem-solving” said Dr. Jing Sun, a postdoctoral scholar at CNSI and an organic chemist. “For the innovative process to yield something useful, it must be faster, better, cheaper and — of course, with microscale technologies — smaller.”

The researchers will next apply the new platform to larger cohorts of cancer patient samples and integrate the diagnostic approach into clinical trials of molecular therapies.

CytoScale Diagnostics has signed a letter of agreement regarding the technology mentioned in this paper.

This study was funded by the National Cancer Institute/ National Institutes of Health (NCI/NIH) and the National Institute of Neurological Disorders and Stroke (NINDS).

The UCLA Crump Institute for Molecular Imaging is a multidisciplinary collaborative of faculty, postdoctoral scholars and graduate students engaged in cutting-edge research in the fields of molecular diagnostics, microfluidics, systems biology and nanotechnology, with the aim of developing new technologies to observe, measure and understand biology in cells, tissues and living organisms through molecular imaging. The institute’s ultimate goal is to provide the technology and science that will lead to a better understanding of the transition from health to disease at the molecular level and the development of new therapies to treat disease as part of a new era in molecular medicine.

UCLA’s Jonsson Comprehensive Cancer Center has more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation’s largest comprehensive cancer centers, the Jonsson Center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2010, the Jonsson Cancer Center was named among the top 10 cancer centers nationwide by U.S. News & World Report, a ranking it has held for 10 of the last 11 years.

The California NanoSystems Institute at UCLA is an integrated research center operating jointly at UCLA and UC Santa Barbara whose mission is to foster interdisciplinary collaborations for discoveries in nanosystems and nanotechnology; train the next generation of scientists, educators and technology leaders; and facilitate partnerships with industry, fueling economic development and the social well-being of California, the United States and the world. The CNSI was established in 2000 with $100 million from the state of California and an additional $250 million in federal research grants and industry funding. At the institute, scientists in the areas of biology, chemistry, biochemistry, physics, mathematics, computational science and engineering are measuring, modifying and manipulating the building blocks of our world — atoms and molecules. These scientists benefit from an integrated laboratory culture enabling them to conduct dynamic research at the nanoscale, leading to significant breakthroughs in the areas of health, energy, the environment and information technology.

Posted in Uncategorized | 1 Comment